Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

# Investor News

**Not intended for U.S. and UK Media**

## Bayer and Onyx Announce New Nexavar® Data To Be Presented at the 2011 ECCO-ESMO Congress

**Leverkusen, September 13, 2011** – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals today announced that results from clinical trials evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

"Through our research and development and clinical trial programs, Bayer and Onyx have established a key role for Nexavar in the treatment of advanced kidney cancer and unresectable liver cancer," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "With data evaluating Nexavar in a variety of treatment settings and patient populations being presented at ECCO-ESMO, the companies continue to demonstrate our commitment to further evaluating Nexavar to determine its safety and efficacy in multiple of tumor types."

Studies evaluating Nexavar being presented at ECCO-ESMO include:

- Second Interim Results of the GIDEON (**G**lobal **I**nvestigation of **T**herapeutic **DE**cisions in HCC and **O**f its Treatment with Sorafe**N**ib) Study: Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup Analysis (abstract #6500)
    - Riccardo Lencioni, M.D., Division of Diagnostic and Interventional Radiology, Cisanello University Hospital, Pisa, Italy
    - Oral Session - Gastrointestinal Malignancies - Noncolorectal Cancer
    - Monday, Sept. 26, 2011, 2:45 p.m. (CET), Hall A6

- PREDICT (**P**atient characteristics in **RE**nal cell carcinoma and **D**aily practI**C**e **T**reatment with Sorafenib) Non-interventional Study: Final Report (abstract #7151)
    - Prof. Dirk Jäger, Director of the National Center for Tumor Diseases, Universitätsklinikum Heidelberg, Medizinische Onkologie, Heidelberg, Germany

    - Poster Session - Genitourinary Malignancies – Other
    - Sunday, Sept. 25, 2011, 2:00-4:30 p.m. (CET), Hall C

- A Double-blind, Randomized Phase IIb Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial (abstract #17)
    - Gabriella Mariani, M.D., Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan
    - LBA Oral Session - Breast Cancer - Advanced Disease
    - Sunday, Sept. 25, 2011, 11:15 a.m. (CET), Hall A1

- A Phase IIb, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial (abstract #19)
    - Josep Tabernero, M.D., Head of the Medical Oncology Department of Vall d'Hebron University Hospital, Barcelona, Spain
    - LBA Oral Session - Gastrointestinal Malignancies - Colorectal Cancer
    - Saturday, Sept. 24, 1:30 p.m. (CET), Victoria Hall

**About Nexavar®**

Nexavar®, an oral anti-cancer therapy for liver cancer and for the treatment of patients with advanced kidney cancer, is currently approved in more than 100 countries worldwide. In Europe, Nexavar is approved for the treatment of hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Nexavar inhibits processes involved in both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR B, KIT, FLT-3 and RET.

Nexavar is also being evaluated in other cancers by Bayer Healthcare, Onyx Pharmaceuticals, international study groups, government agencies and individual investigators.

**About Onyx Pharmaceuticals, Inc.**
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

**About Bayer HealthCare**
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)
Ute Menke (+49-214-30-33021)

**Forward-Looking Statements**
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.